Humanized anti-complement factor bb antibodies and uses thereof
AssigneeGenzyme Corporation
InventorsGraham Parry, Stephen Moore, Michael J. Storek, Nina C. Leksa
Life of this patent
Estimating the term…
Abstract
Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.
Claims22
A humanized antibody that binds specifically to human complement factor Bb protein, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 27.
2-17. (canceled)
22-23. (canceled)
A method of treating a subject having a complement-mediated disease or disorder, wherein the method comprises administering to the subject a therapeutically effective amount of a humanized antibody that binds specifically to human complement factor Bb protein, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 27.
A method of inhibiting a complement pathway activity in a subject, wherein the method comprises administering to the subject a humanized antibody that binds specifically to human complement factor Bb protein, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 27.
A humanized antibody that binds specifically to human complement factor Bb protein and comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 17 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 26.
Dependencies are inferred from the claim text.